Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-900-4520
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees49
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) announced its quarterly earnings data on Thursday, August, 1st. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.02. View Corvus Pharmaceuticals' Earnings History.
When is Corvus Pharmaceuticals' next earnings date?
What price target have analysts set for CRVS?
4 brokerages have issued 12-month price targets for Corvus Pharmaceuticals' stock. Their predictions range from $6.00 to $11.00. On average, they expect Corvus Pharmaceuticals' share price to reach $8.00 in the next year. This suggests a possible upside of 124.7% from the stock's current price. View Analyst Price Targets for Corvus Pharmaceuticals.
What is the consensus analysts' recommendation for Corvus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corvus Pharmaceuticals.
What are Wall Street analysts saying about Corvus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Corvus Pharmaceuticals stock:
- 1. Mizuho analysts commented, "We initiate coverage of CRVS at $7 PT. We like the adenosine (ADO)-A2AR pathway and believe there is promise in combination therapy. The shares have struggled due to, in our view, underwhelming ciforadenant monotherapy data but we see CPI-006 as the opportunity to reset expectations." (9/11/2019)
- 2. According to Zacks Investment Research, "Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. " (7/15/2019)
Has Corvus Pharmaceuticals been receiving favorable news coverage?
News coverage about CRVS stock has been trending somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Corvus Pharmaceuticals.
Are investors shorting Corvus Pharmaceuticals?
Corvus Pharmaceuticals saw a increase in short interest in August. As of August 15th, there was short interest totalling 1,139,000 shares, an increase of 34.2% from the July 15th total of 848,500 shares. Based on an average daily trading volume, of 209,300 shares, the short-interest ratio is currently 5.4 days. Approximately 5.8% of the company's stock are short sold. View Corvus Pharmaceuticals' Current Options Chain.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Arcus Biosciences (RCUS), Obseva (OBSV), AMAG Pharmaceuticals (AMAG), Crinetics Pharmaceuticals (CRNX), Karuna Therapeutics (KRTX), Beyondspring (BYSI), XBiotech (XBIT), Collegium Pharmaceutical (COLL), CymaBay Therapeutics (CBAY), Cyclerion Therapeutics (CYCN), Assembly Biosciences (ASMB), Lexicon Pharmaceuticals (LXRX), DURECT (DRRX), Protagonist Therapeutics (PTGX) and AC Immune (ACIU).
What other stocks do shareholders of Corvus Pharmaceuticals own?
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
- Mr. Leiv Lea, Chief Financial Officer (Age 65)
- Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
- Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
- Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Who are Corvus Pharmaceuticals' major shareholders?
Corvus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (22.34%), Price T Rowe Associates Inc. MD (6.00%), Renaissance Technologies LLC (2.83%), Cowen Inc. (1.96%), Cowen Inc. (1.96%) and Vanguard Group Inc. (1.66%). Company insiders that own Corvus Pharmaceuticals stock include Adams Street Partners Llc, Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.
Which major investors are selling Corvus Pharmaceuticals stock?
Which major investors are buying Corvus Pharmaceuticals stock?
CRVS stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Paloma Partners Management Co, Vanguard Group Inc., Parametric Portfolio Associates LLC, Fosun International Ltd and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Adams Street Partners Llc, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Insider Buying and Selling for Corvus Pharmaceuticals.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $3.56.
How big of a company is Corvus Pharmaceuticals?
What is Corvus Pharmaceuticals' official website?
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
